Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mina Nikanjam

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Cureus|February 2, 2019
Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) ExperienceMina Nikanjam, Jason Wing, Edmund Capparelli, et al.
The Oncologist|April 21, 2017
Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 PatientsMina Nikanjam, Sariah Liu, Jincheng Yang, et al.
Journal of Medical Case Reports|August 31, 2022
Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case seriesMina Nikanjam, Jaren Mullen, Carol Yacoub, et al.
Cancer|December 4, 2019
Targeting fusions for improved outcomes in oncology treatmentMina Nikanjam, Ryosuke Okamura, Donald A Barkauskas, et al.
Molecular Cancer Therapeutics|March 16, 2021
<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic OutcomesMina Nikanjam, Jose Tinajero, Donald A Barkauskas, et al.
Cancer Treatment Reviews|April 7, 2020
Review of precision cancer medicine: Evolution of the treatment paradigmApostolia M Tsimberidou, Elena Fountzilas, Mina Nikanjam, et al.
European Journal of Cancer (Oxford, England : 1990)|October 13, 2023
At the right dose: personalised (N-of-1) dosing for precision oncologyMina Nikanjam, Shumei Kato, Jason K Sicklick, et al.
Clinical Oncology, Case Reports|April 11, 2022
Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion AlterationsMina Nikanjam, Shumei Kato, Jacob J Adashek, et al.
Cancer Letters|April 10, 2025
Nectin-4 expression patterns and therapeutics in oncologyMina Nikanjam, Judith Pérez-Granado, Mark Gramling, et al.
CA: a Cancer Journal for Clinicians|January 22, 2025
Novel clinical trial designs emerging from the molecular reclassification of cancerMina Nikanjam, Shumei Kato, Teresa Allen, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Cureus|February 2, 2019
Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) ExperienceMina Nikanjam, Jason Wing, Edmund Capparelli, et al.
The Oncologist|April 21, 2017
Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 PatientsMina Nikanjam, Sariah Liu, Jincheng Yang, et al.
Journal of Medical Case Reports|August 31, 2022
Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case seriesMina Nikanjam, Jaren Mullen, Carol Yacoub, et al.
Cancer|December 4, 2019
Targeting fusions for improved outcomes in oncology treatmentMina Nikanjam, Ryosuke Okamura, Donald A Barkauskas, et al.
Molecular Cancer Therapeutics|March 16, 2021
<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic OutcomesMina Nikanjam, Jose Tinajero, Donald A Barkauskas, et al.
Cancer Treatment Reviews|April 7, 2020
Review of precision cancer medicine: Evolution of the treatment paradigmApostolia M Tsimberidou, Elena Fountzilas, Mina Nikanjam, et al.
European Journal of Cancer (Oxford, England : 1990)|October 13, 2023
At the right dose: personalised (N-of-1) dosing for precision oncologyMina Nikanjam, Shumei Kato, Jason K Sicklick, et al.
Clinical Oncology, Case Reports|April 11, 2022
Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion AlterationsMina Nikanjam, Shumei Kato, Jacob J Adashek, et al.
Cancer Letters|April 10, 2025
Nectin-4 expression patterns and therapeutics in oncologyMina Nikanjam, Judith Pérez-Granado, Mark Gramling, et al.
CA: a Cancer Journal for Clinicians|January 22, 2025
Novel clinical trial designs emerging from the molecular reclassification of cancerMina Nikanjam, Shumei Kato, Teresa Allen, et al.
Pageof 7